Action for Pulmonary Fibrosis > News > Uncategorised > Access to your medicines after Brexit.

Access to your medicines after Brexit.

Some patients with idiopathic pulmonary fibrosis and their carers have queried the availability of the anti-fibrotic drugs Pirfenidone (made by Roche) and Nintedanib (made by Boehringer Ingelheim) after Brexit. 

We contacted both manufacturers who have said that they have been in planning since the result of the EU referendum in 2016.  Both companies have focused on building strong supply chains and have increased UK stock levels as part of a series of measures to maintain ease of access to their medicines.

You can keep up to date with any developments from Roche or Boehringer Ingelheim by clicking on the links. 

You can also click here for practical information from the NHS.

We shall update our website if there are any changes to this information.

Sign up to receive our newsletter

Never miss our news—sign up to receive our quarterly newsletter and we'll keep you updated about any important announcements, new research and lots of fundraiser stories.